This website is intended for US Healthcare Professionals.

CONTact Your MSL

Clinical Trials

Explore Arvinas-Sponsored Clinical Trials 

Find trials that may be relevant for you and your patients. 

Arvinas Clinical Trial Finder

Arvinas Development Program
Explore our development pipeline of PROTAC® protein degraders.

Development Pipeline

Enrolling Oncology Clinical Trials

Learn more about our enrolling clinical trials.

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

Vepdegestrant

VERITAC-2
A phase 3, randomized, open-label study of vepdegestrant (ARV-471) vs fulvestrant in patients with ER+/HER2- advanced breast cancer

VERITAC-3
A phase 3, randomized, open-label, study of vepgedestrant (ARV-471) plus palbociclib vs letrozole plus palbociclib in patients with ER+/HER2- advanced breast cancer

TACTIVE-U
A phase 1b/2 umbrella study of vepdegestrant (ARV-471) in combination with other anticancer treatments in patients with ER+ advanced or metastatic breast cancer

TACTIVE-K
A phase 1b/2 open-label study of vepdegestrant (ARV-471) in combination with PF-07220060 (a CDK4 inhibitor) in patients with ER+/HER2- advanced or metastatic breast cancer 

ARV-766

ARV-766-mCRPC-101

A phase 1/2 open-label study of ARV-766 in patients with metastatic castration-resistant prostate cancer and progression on prior systemic therapies

ARV-393

ARV-393-101
A phase 1 first-in-human, open-label, dose-escalation study of ARV-393 in adult patients with advanced non-Hodgkin lymphoma

Prostate Cancer

ARV-766-mCRPC-101

A phase 1/2 open-label study of ARV-766 in patients with metastatic castration-resistant prostate cancer and progression on prior systemic therapies

Arvinas Oncology Medical

You are now leaving arvinasoncologymedical.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

YES, I AM AN HCP

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.

I AM NOT AN HCP